Cite
HARVARD Citation
Muhammad, A. et al. (2018). Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. European journal of endocrinology. 179 (5), pp. 269-277. [Online].